AbbVie (ABBV)
NYSEHealth CareDrug Manufacturers - GeneralSnapshot 2026-09-04
$256.46-1.44%
Close 2026-09-04 · 1-day change
NYSEHealth CareDrug Manufacturers - GeneralSnapshot 2026-09-04
QuarterlyIQ Insights · ABBV
Price, fair value, and the multiples that frame it on the same time axis. Scroll over the price chart to zoom.
Daily closes. Earnings/event dots inline.
A consensus fair price across 10 valuation methods, at three horizons. As of 2026-09-04. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
We take the 12-month fair value above and grade our own number — how the market prices this name versus what we'd justify, and where the two diverge.
At $256 ABBV trades at 24× p/e, in line with its 22× p/e peer median, and our $241 fair value agrees. We hold it with medium confidence: quality doesn't explain valuation multiples in this sub-industry, so the peer comparison is a weak guide. Analysts target $235–$303. Even valued only for durable growth at sustainable margins, it's worth about $298 — above today's price, so the premium reflects that growth case, not pure multiple expansion. Not investment advice.
One valuation read at a 12-month horizon, plus how price compares to peers and the company's own history.
Score 100 = cheapest in the cohort, 0 = richest. Bars are filled left-to-right based on the peer-relative score (or PEG/self-history where shown).
Each method's implied share price per horizon. Provisional rows use a projected (historical-CAGR) growth input rather than analyst or management guidance.
| Method | Horizon | Est. price | Multiple | Per-share input | EPS source | Confidence |
|---|---|---|---|---|---|---|
| analyst target | 12M | $290.00 | — | — | Analyst | high |
| dcf fcfe | 12M | $93.42 | — | — | Hist. CAGR | high |
| dcf fcff | 12M | $81.70 | — | — | Hist. CAGR | high |
| ddm gordon | 12M | $32.49 | — | — | TTM | high |
| Mgmt guidance | 12M |
A “consensus-then vs. actual-now” overlay is on the way — what our valuation estimate said on a past date versus where the price actually landed.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
A long-thesis check that carries the widest uncertainty of the three horizons.
Above average on quality vs scored peers
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
$235.00 – $303.00 (median $290.00) · 19 analysts · as of 2026-08-20
No fragility gates fired. Regime (Mania) does not concentrate fragility.
For similar setups historically (n=20,154): about 33% saw a 20%+ drawdown, and roughly 76% of those did not recover within the year. These are historical base rates for the cohort, not a forecast of this stock.
At today's price you pay about 96% over what the business is worth with no growth; closing that gap needs roughly 12.0 years of the forecast growth to come through. These describe the expectations embedded in the price, not a forecast of the move. Reverse-DCF base: $7.54/sh owner earnings.
Roughly priced in line with peers.
Self-history needs ~20 months of data.
Trailing four: 2025-Q3, 2025-Q4, 2026-Q1, 2026-Q2
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
| $307.20 |
| 22.0 |
| 13.97 |
| Mgmt |
| high |
| Peer P/FCF | 12M | $221.14 | 21.6 | 10.25 | TTM | high |
| Peer P/E | 12M | $253.07 | 18.1 | 13.97 | ntm analyst | high |
| Peer P/S | 12M | $413.80 | 11.4 | 36.36 | TTM | high |
| PEG | 12M | $193.45 | 13.8 | 13.97 | TTM | high |
| triangulated | 12M | $240.92 | 22.0 | 10.96 | Triangulated | high |
| Mgmt guidance | 3Y | $772.00 | 22.0 | 35.11 | Mgmt(prov.) | medium |
| Peer P/FCF | 3Y | $161.80 | 21.6 | 7.50 | Hist. CAGR(prov.) | medium |
| Peer P/E | 3Y | $351.28 | 18.1 | 19.39 | Analyst | medium |
| Peer P/S | 3Y | $560.09 | 11.4 | 49.21 | Analyst | medium |
| PEG | 3Y | $268.53 | 13.8 | 19.39 | Analyst | medium |
| Mgmt guidance | 5Y | $1426.99 | 22.0 | 64.89 | Mgmt(prov.) | medium |
| Peer P/FCF | 5Y | $131.37 | 21.6 | 6.09 | Hist. CAGR(prov.) | medium |
| Peer P/E | 5Y | $427.77 | 18.1 | 23.61 | Analyst | medium |
| Peer P/S | 5Y | $682.05 | 11.4 | 59.92 | Analyst | medium |
| PEG | 5Y | $327.00 | 13.8 | 23.61 | Analyst | medium |